c-rel

IT-901 is an orally active and potent NF-κB subunit c-Rel inhibitor with IC50 values for NF-κB and c-Rel binding to DNA of 0.1 µM and 3 µM, respectively. IT-901 is a naphthalene thiobarbiturate derivative with antitumor activity and is used for the prevention and treatment of human lymphoma and myeloma.

(E/Z)-IT-603 is a cell-permeable c-Rel inhibitor (IC50: 3μM) that directly and reversibly binds to c-Rel, altering its conformation and inhibiting its DNA binding and transcriptional activity.

Pancreatin (pancrelipase) is a mixture of several digestive enzymes secreted by the exocrine cells of the pancreas. It is composed of amylase, lipase and protease.

Gemfibrozil (CI-719) interacts with peroxisome proliferator-activated receptors (PPARalpha) resulting in PPARalpha-mediated stimulation of fatty acid oxidation and an increase in lipoprotein lipase (LPL) synthesis. Gemfibrozil is a fibric acid derivative with hypolipidemic effects. This enhances triglyceride-rich lipoprotein clearance and reduces the expression of apolipoprotein C-III (apoC-III). The reduction in hepatic production of apoC-III result in the subsequent reduction of serum levels of very-low-density-lipoprotein cholesterol (VLDL-C). In addition, gemfibrozil-mediated PPARalpha stimulation of apoA-I and apoA-II expression results in an increase in high-density lipoprotein cholesterol (HDL-C).

Crelosidenib is an inhibitor specifically targeting isocitrate dehydrogenase 1 (IDH1) and also functions as an antineoplastic compound.

Crelosidenib is a potent and selective mutant IDH inhibitor with IC50s of 6.27 nM, 3.71 nM, 36.9 nM, and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q, and IDH2 R172K mutases, respectively, and low inhibitory activity against the wild-type IDH enzyme.

Hypocrellin A is a natural PKC inhibitor with light-induced antitumor, antifungal and antiviral activities and also exerts immunomodulatory effects on MHC-restricted antigen presentation.

HYPOCRELLIN B are photosensitive pigments isolated from Hypocrella bambusae Sacc. Hypocrellin B causes DNA strand breakage, induces apoptosis in ovarian cancer cells, and inhibits proliferation of Staphylococcus by increasing ROS levels, and damaging cell

Ocrelizumab (IDC-2403) is a humanized monoclonal antibody directed against CD20 for the treatment of multiple sclerosis.

Selicrelumab (RG-7876) is an antibody targeting CD40 with potential anti-tumor activity that induces changes in the tumor microenvironment in patients with resectable pancreatic cancer and may be used to study pancreatic cancer.

Hypocrellin C is a natural product isolated from fungi exhibiting antimicrobial activity against Candida albicans.

Cyclopenta[c][1]benzopyran-8-ol, 1,2,3,3a,4,9b-hexahydro-4-(4-hydroxyphenyl)-, (3aR,4S,9bS)-rel- is an estrogen receptor beta (ERβ) agonist.

AS2677131 is a potent and orally active PIKfyve inhibitor. It suppresses IL-12p40, IL-6, and IL-1β through the PIKfyve-c-Rel pathway and selectively inhibits the DNA-binding activity of c-Rel with IL-12p40 and IL-1β promoters. Additionally, AS2677131 represses the expression of MHCII molecules on B cells. This compound is applicable for research in inflammation and immunology, such as in arthritis.

rel-Avibactam (NXL-104) sodium is a β-lactamase inhibitor with broad-spectrum antibacterial activity. When combined with Ceftazidime, rel-Avibactam sodium exhibits significant inhibitory effects on Enterobacteriaceae producing Ambler class A and C β-lactamases. Its IC50 values are significantly lower than those of commonly used β-lactamase inhibitors like Clavulanic acid and Ticarcillin, demonstrating high efficacy against TEM-1 and P99 enzymes.

MI-2 (MALT1 inhibitor) is an irreversible MALT1 inhibitor.

(rel)-Tivantinib is a potent, highly selective inhibitor of the receptor tyrosine kinase c-MET and has additional novel targets, GSK3α and GSK3β, that are critical in the cellular mechanisms of non-small cell lung cancer (NSCLC) [1].

DC-SX029 is a potent inhibitor of SNX10 protein-protein interaction (PPI) with an estimated K D constant of approximately 0.935 μM as measured by surface plasmon resonance (SPR). It blocks the SNX10-PIKfyve interaction, leading to decreased TBK1/c-Rel signaling activation, without affecting SNX10 protein levels. DC-SX029 shows potential for inflammatory bowel disease (IBD) research [1].

rel-(7R,8'R,8S)-Forsythialan C (compound 9) is a lignan compound that can be isolated from Forsythia suspensa.

rel-2-(tert-Butoxycarbonyl)octahydrocyclopenta[c]pyrrole-3a-carboxylic acid is a pharmaceutical intermediate used in the synthesis of various active compounds.